Quantum BioPharma Ltd. (QNTM)
QNTMNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.02
-0.0200 (-0.98%) today
Pre-market, Nov 10, 4:00 PM ET
- Market cap
- $17.11m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.04 to $12.42
- Average volume
- 150.5k
- Previous close
- $2.04
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $8.00, +296.0% from here
Earnings
Next report Nov 13, 2026
Financials
No quarterly figures from the source.
News
8 latest- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets BuiltMarketBeat · Oct 14, 2026
- Quantum BioPharma Advances Lucid-MS Into Phase 2 Development With Thermo Fisher Partnership RTTNews · Oct 6, 2026
- Clinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More RTTNews · Sep 9, 2026
- Quantum BioPharma Receives FDA Clearance For Lucid-MS Phase 2 Trial RTTNews · Sep 9, 2026
- Quantum: FDA Approves IND For Lucid-MS; To Engage CRO To Support Implementation Of Phase 2 Study RTTNews · Aug 10, 2026
- Quantum BioPharma (QNTM) Price Target Increased by 10.88% to 36.72Fintel · Apr 28, 2026
- Quantum BioPharma Submits IND To FDA For Lucid-MS In Multiple Sclerosis For Phase 2 Trial; Stock Up RTTNews · Apr 1, 2026
- Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength RTTNews · Dec 21, 2025
The company
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (' Lucid '), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc. (' Unbuzzd ') (formerly Celly Nutrition Corp. ), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026 ) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd until payments to Quantum total $250 million .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- quantumbiopharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.